EDIT News and Press, Editas Medicine Inc. From 01/19/23

Editas Medicine ( NASDAQ: EDIT ) announced an agreement with privately-held Shoreline Biosciences on Thursday to sell its natural killer cell ((iNK)) programs and related manufacturing technologies. As part of the deal, Shoreline will also obtain an exclusive license to Editas’...

Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for AsCas12a Shoreline to acquire Editas Medicine’s iNK cell franchise, including ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CRISPR could revolutionize the way we treat thousands of diseases.  Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material,  the Cleveland Clinic reported ....

Summary CRISPR Therapeutics is probably the most widely-known company utilizing the original CRISPR-Cas9 gene editing method. Prime editing is a newer variation on CRISPR-Cas9 which is safer since it doesn't produce double-strand breaks in DNA. During the market turmoil of late last...

Editas Medicine, Inc. (EDIT) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 07:30 PM ET Company Participants Gilmore O’Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Michelle Robertson - Chief Financial Officer Conferen...

Shares of Editas Medicine (NASDAQ: EDIT) are sliding today, down by 7.2% as of 11:26 a.m. ET. The decline came after the company announced a big shake-up with its research and development focus. Editas stated that it won't invest any further in inherited retinal disease programs. Thes...

Editas Medicine ( NASDAQ: EDIT ) announced a ~20% reduction to the headcount on Monday amid a strategic reprioritization of its portfolio targeting hemoglobinopathies and in vivo gene editing. Accordingly, the company has decided to focus its resources on EDIT-301, its lead program ta...

Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing Discontinuing internal investments in inherited retinal diseases and in preclinical wholly owned iNK programs Mark S. Shearman, Ph.D., Chief Scientific Officer to step down, departi...

Summary While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific. Now that the tax loss bloodbath is over, here are some po...

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 41st Annual J.P. Morgan Healthcare Conference o...